AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

18.11.24	European Commission Approves AbbVie's ELAHERE For Platinum-Resistant Ovarian Cancer Treatment (RTTNews)
11.11.24	AbbVie Says Phase 2 Trials Of Emraclidine In Schizophrenia Did Not Meet Primary Endpoint (RTTNews)
31.10.24	AbbVie, EvolveImmune To Develop Multispecific Biologics For Multiple Targets In Oncology (RTTNews)
30.10.24	AbbVie Boosts FY24 Outlook; Boosts Dividend 5.8% - Update (RTTNews)
30.10.24	AbbVie Q3 Profit Decreases, But Beats Estimates (RTTNews)
28.10.24	AbbVie Agrees To Acquire Aliada Therapeutics For $1.4 Bln In Cash (RTTNews)
21.10.24	AbbVie Gets Accelerated Public Reimbursement Approval Of Epkinly In Nine Canadian Provinces (RTTNews)
19.10.24	Allergan Aesthetics: FDA Approves BOTOX® Cosmetic For The Treatment Of Platysma Bands (RTTNews)
17.10.24	FDA Approves AbbVie's Parkinson's Disease Drug Vyalev (RTTNews)
03.10.24	AbbVie Cuts Q3, FY Adj. EPS Outlook (RTTNews)
28.09.24	AbbVie Submits BLA To FDA For Telisotuzumab Vedotin In Previously Treated Non-Small Cell Lung Cancer (RTTNews)
26.09.24	AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase 3 Trial In Early Parkinson's Disease (RTTNews)
25.09.24	AbbVie: Upadacitinib Phase 3 Trials' Post-hoc Analysis Show Positive Results In Atopic Dermatitis (RTTNews)
20.09.24	AbbVie: CHMP Adopts Positive Opinion For Mirvetuximab Soravtansine - Quick Facts (RTTNews)
10.09.24	AbbVie Says Health Canada Approves CONSTELLA To Treat Functional Constipation In Pediatric Patients (RTTNews)
04.09.24	AbbVie: CDA Issues Positive Reimbursement Recommendation For VRAYLAR In Treatment Of Schizophrenia (RTTNews)
20.08.24	AbbVie's Tepkinly Gets Conditional EU Approval For Relapsed Or Refractory Follicular Lymphoma (RTTNews)
01.08.24	AbbVie Completes Acquisition Of Cerevel; Reaffirms Full-year Adj. EPS Guidance Range (RTTNews)
26.07.24	European Commission Approves AbbVie's Skyrizi To Treat Ulcerative Colitis (RTTNews)
25.07.24	AbbVie Boosts FY24 Outlook - Update (RTTNews)
25.07.24	AbbVie Q2 Profit Decreases, But Beats Estimates (RTTNews)
12.07.24	AbbVie Seeking FDA And EMA Approval For Upadacitinib In Giant Cell Arteritis (RTTNews)
10.07.24	AbbVie Appoints Thakkar As EVP Of R&D, Chief Scientific Officer (RTTNews)
01.07.24	AbbVie's Robert Michael Assumes Role Of CEO (RTTNews)
28.06.24	AbbVie: CHMP Adopts Positive Opinion Recommending Conditional Marketing Authorization Of Epcoritamab (RTTNews)
27.06.24	AbbVie Acquires Celsius Therapeutics For $250 Mln (RTTNews)
27.06.24	Genmab's EPKINLY Receives FDA Accelerated Approval For R/R Follicular Lymphoma (RTTNews)
25.06.24	AbbVie: FDA Issues CRL For ABBV-951 (RTTNews)
19.06.24	AbbVie's Skyrizi Gets Approval In US For Ulcerative Colitis (RTTNews)
13.06.24	AbbVie To Receive License From FutureGen To Develop, Commercialize FG-M701 (RTTNews)
06.06.24	AbbVie Reports Positive Results From Phase 2 PICCOLO Trial Of Mirvetuximab Soravtansine In PSOC (RTTNews)
04.06.24	AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients (RTTNews)
31.05.24	AbbVie: Risankizumab Recommended For EU Approval For Moderately-Severely Active Ulcerative Colitis (RTTNews)
13.05.24	AbbVie To Collaborate With Gilgamesh To Develop Next-Gen Psychiatric Therapies (RTTNews)
08.05.24	AbbVie's Qulipta Gets Health Canada Approval For Chronic Migraine In Adults (RTTNews)
26.04.24	AbbVie Lifts FY24 Outlook After Higher Q1 Results - Update (RTTNews)
26.04.24	AbbVie Q1 Profit Increases, beats estimates (RTTNews)
25.04.24	AbbVie's Rinvoq Shows Positive Results Over Dupixent In Atopic Dermatitis Study (RTTNews)
18.04.24	AbbVie's Phase 3 Study Of Upadacitinib Achieves Primary Endpoint In Giant Cell Arteritis (RTTNews)
25.03.24	AbbVie To Acquire Landos Biopharma At $20.42/share In Cash (RTTNews)
24.03.24	FDA Fully Approves AbbVie's Elahere For Ovarian Cancer (RTTNews)
05.03.24	AbbVie's Allergan Aesthetics Gets FDA Nod For Juvederm Voluma XC For Temple Hollows (RTTNews)
28.02.24	AbbVie To Receive Global License To Develop OSE-230 From OSE Immunotherapeutics (RTTNews)
27.02.24	Genmab's SBLA For Epcoritamab-bysp Granted Priority Review By FDA (RTTNews)
22.02.24	AbbVie Teams Up With Tentarix To Develop Multi-specific Biologics For Oncology, Immunology (RTTNews)
20.02.24	AbbVie Appoints President And COO Robert Michael To Addl. Role Of CEO (RTTNews)
12.02.24	AbbVie Cuts Q1 Earnings Outlook, Below View (RTTNews)
08.02.24	AbbVie's Vyalev Now Available For Advanced Parkinson's Disease In Canada (RTTNews)
07.02.24	Calibr-Skaggs, AbbVie To Develop Novel Cell Therapies For Solid Tumors And Autoimmune Diseases (RTTNews)
02.02.24	AbbVie Expects Annual Earnings In Line With View (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus

11.11.24

NYSE-Handel: S&P 500 mittags freundlich

11.11.24

Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

02.07.24

Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge

02.07.24

Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten

06.05.24

S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude

26.04.24

Gewinne in New York: S&P 500 am Nachmittag fester

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

Nachrichten zu AbbVie Inc

Aktien Top/Flop

AbbVie Peer Group Nachrichten

Meistgelesene Nachrichten